financetom
Business
financetom
/
Business
/
Crude should be in the range of $60-65/bbl in near term, says HPCL's MD
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Crude should be in the range of $60-65/bbl in near term, says HPCL's MD
Feb 22, 2021 4:16 AM

Crude prices have increased by 40 percent in the last three months and fuel prices are at record highs. MK Surana, Chairman and MD, Hindustan Petroleum Corporation Ltd (HPCL) spoke about this.

Share Market Live

NSE

The current hike in crude prices is a result of some factors like cold weather in the US, some sort of uncertainty in the Organization of the Petroleum Exporting Countries (OPEC) direction regarding production cuts and also an earthquake in Japan which led to some sort of disruptions in supplies, he said.

He assumes some of these shall go away.

“Going forward, we think that probably the crude should be in the range of $60-65 per barrel or somewhere around $60 per barrel,” said Surana.

Demand right now is a function of many factors.

“As far as demand for petrol is concerned, in the month of January, we saw the rise of around 6.5 percent over last year. Even in the February month, we saw the demand of around 5 percent up compared to what we saw in February up to this period,” he mentioned.

“There is a good pick up in aviation turbine fuel (ATF). It is almost reaching 60-65 percent of the pre-COVID levels. Liquefied petroleum gas (LPG) has always been high, the industry products had been good. Overall I cannot conclude anything as far as pricing is concerned,” Surana pointed out.

In terms of the possibility of a strict lockdown in Maharashtra as the number of COVID-19 patients is on the rise, he mentioned, “I assume a complete lockdown is unlikely now. I think there may be more compliance level, more marshaling to ensure that all the guidelines are followed other than the complete lockdown. If that happens, the demand effect may be lesser or may not be there.”

On liquefied natural gas (LNG) stations, he said, “We do have the LNG in our portfolio. We have got around 600 stations from which we dispense CNG and we are putting up around 11 stations that will dispense LNG. On the city gas distribution (CGD) front, over the next five years, we have a plan of around 8,000 which includes our LNG terminals.”

“We have got around close to 45 stations Electric vehicles (EV) where we have put up the charging stations and we are in this space and we will develop it as it goes,” he added.

For the full interview, watch the video…

(Edited by : Anshul)

First Published:Feb 22, 2021 1:16 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Wingstop Q3 system-wide sales rise 10%, helped by new restaurants
Wingstop Q3 system-wide sales rise 10%, helped by new restaurants
Nov 4, 2025
Overview * Wingstop ( WING ) fiscal Q3 system-wide sales rise 10% to $1.4 bln * Adjusted EBITDA for fiscal Q3 grows 18.6% to $63.7 mln, highest quarter on record * Company opened 114 net new restaurants, achieving 19.3% net new unit growth Outlook * Wingstop ( WING ) revises 2025 domestic same store sales growth to decline 3%-4% *...
Hillman Q3 net sales rise 8%, beat estimates
Hillman Q3 net sales rise 8%, beat estimates
Nov 4, 2025
Overview * Hillman Q3 2025 net sales rise 8% to record $424.9 mln, beating analyst expectations * Adjusted EPS for Q3 2025 beats consensus, reaching $0.22 per share * Company repurchased 325.6 thousand shares, totaling $3.2 mln Outlook * Hillman maintains FY 2025 net sales guidance at $1.535 to $1.575 bln * Company raises FY 2025 adjusted EBITDA guidance to...
BRIEF-Evoke Pharma Enters Into Definitive Agreement To Be Acquired By QOL Medical
BRIEF-Evoke Pharma Enters Into Definitive Agreement To Be Acquired By QOL Medical
Nov 4, 2025
Nov 4 (Reuters) - Evoke Pharma Inc ( EVOK ): * EVOKE PHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY QOL MEDICAL * EVOKE PHARMA INC ( EVOK ): PROPOSED DEAL FOR FOR $11.00 PER SHARE IN CASH AT CLOSING Source text: Further company coverage: ...
Nuvectis Pharma Q3 net loss widens
Nuvectis Pharma Q3 net loss widens
Nov 4, 2025
Overview * Nuvectis Q3 net loss widens to $7.5 mln, driven by milestone and study costs * Cash position improves to $35.4 mln, supported by public offering and ATM facility * NXP900 Phase 1b program initiated, showcasing therapeutic potential in advanced cancers Outlook * Cash runway expected to support operations into 3Q-2027 Result Drivers * Research and development expenses were...
Copyright 2023-2026 - www.financetom.com All Rights Reserved